If you look at the 'Big New' email sent by IBX on the 6th Feb...

If you look at the 'Big New' email sent by IBX on the 6th Feb and click on ' Read the Announcement' it gives a much clearer picture.
The Presentation was extremely unclear and on its own a little misleading.
Duke2 is right Magsense kicks in after a cancer diagnosis. The presentation fails to mention this.
From the email Extract
" How MagSense® with MRI addresses the unmet need
After a new breast cancer diagnosis, the patient is assessed for metastatic disease, initially by nodal staging. This involves a combination of clinical assessment and radiographic imaging. Precise nodal staging is an essential component in the management of patients with breast cancer, as treatments depend on patient-specific characteristics of the primary tumor, nodal status, and evaluation for distant metastatic disease. The use of imaging varies widely based on available resources and institutional experience with ultrasound being the more common method for nodal assessment. However, ultrasound is limited to morphological assessment (node size and shape), is limited in the area that can be scanned, and is highly dependent on the experience of the operator. As a result, diagnostic sensitivity and specificity is highly variable and so whether there is a suspected presence of abnormal nodes or not, a patient will typically be required to have additional evaluation by biopsy and pathologic confirmation. Recently the breast cancer community has been making a push towards “de-escalation of axillary surgery”, i.e. reducing node removals and biopsies.
MRI is well suited to image soft tissues of the body, is less dependent on operator experience, and can scan the entire nodal region. However, it is also limited to identifying “regions of interest” based on anatomical or morphological abnormalities. Whilst current contrast agents, such as gadolinium, can improve general image signal-to-noise ratios they are non-specific, i.e. they do not target the molecular phenotype of cancer cells, and therefore cannot specify if tumour cells are present.
It is within this clinical context that Imagion’s noninvasive and molecularly targeted, tumor-specific approach can add value. With more than 30,000 clinical-grade scanners globally, MRI is a ubiquitous and accessible imaging technology. If brought to market for use in conjunction with such a well-accepted imaging modality, the Company’s MagSense® technology would be the first molecular imaging agent developed for Magnetic Resonance Imaging and can change the way we look at cancer. "
IBX have said in the Presentation that they will build a portfolio of Imaging Agents for each specific type of cancer.
So numbers are limited to actual cancer diagnosis cases for each specific type of cancer.
There may be potential for patient management MRI's during treatment and after??